1. Stem Cell/Wnt TGF-beta/Smad PI3K/Akt/mTOR Apoptosis
  2. TGF-beta/Smad PI3K Apoptosis
  3. Disitertide TFA

Disitertide TFA  (Synonyms: P144 TFA)

目录号: HY-P0118A
产品使用指南

Disitertide (P144) TFA 是转化生长因子 TGFβ1 的多肽抑制剂,特异性的阻断其与受体间的相互作用。Disitertide TFA 也是PI3K 的抑制剂和凋亡 (apoptosis) 诱导剂。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Custom Peptide Synthesis

Disitertide TFA Chemical Structure

Disitertide TFA Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Disitertide TFA 的其他形式现货产品:

Customer Review

Other Forms of Disitertide TFA:

注册 MCE会员完成审核
即刻享有 积分商城 300 专属积分

Top Publications Citing Use of Products

    Disitertide TFA purchased from MCE. Usage Cited in: Cell Death Differ. 2021 Jan;28(1):219-232.  [Abstract]

    LINC00941-overexpressing cells treated with Disitertide (10 μM) shows increased mRNA and protein levels of ZO-1 and Ecadherin compared with controls. LINC00941-silenced cells show decreased mRNA and protein levels of ZO-1 and E-cadherin but increased mRNA and protein levels of Vimentin, Fibronectin, and Twist1.
    • 生物活性

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer[1][2][3][4][5].

    IC50 & Target

    TGF-β1, P13K[1][2].

    体外研究
    (In Vitro)

    Disitertide (P144,100 μg/mL) TFA 抑制 PI3K 和 p-Akt 的蛋白表达水平,并诱导 MC3T3-E1 细胞中 Bax 的蛋白表达[2]
    (TGF-β1 inhibitor) TFA 抑制 GC 细胞中 MACC1-AS1 的表达,表明靶向 TGF-β 信号通路可能是抑制 MSC 诱导的干细胞和化疗耐药的潜在策略[3]
    Disitertide (10 μg/mL 至 200 μg/mL) TFA 影响 A172 和 U-87 MG GBM 细胞系的增殖、诱导细胞凋亡和失巢凋亡[5]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Western Blot Analysis[2]

    Cell Line: Mouse embryo osteoblast precursor MC3T3-E1 cells.
    Concentration: 100 μg/mL.
    Incubation Time: 4 h.
    Result: Significantly suppressed the protein expression levels of PI3K and p-Akt, and induce the protein expression of Bax in MC3T3-E1 cells compared with the miR-590 group.
    体内研究
    (In Vivo)

    Disitertide (P144,Topical application,300 μg/mL) TFA 在裸鼠“体内”模型中处理两周后可促进瘢痕成熟并改善增生性瘢痕形态特征[4]

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Human hypertrophic scars were implanted in 60 nude mice[4].
    Dosage: 300 μg/mL was added the Lipogel.
    Administration: Topical application daily administered.
    Result: Successful shedding was achieved in 83,3% of the xenografts.
    Clinical Trial
    分子量

    1580.82 (free acid)

    Formula

    C68H109N17O22S2.xC2HF3O2

    性状

    固体

    颜色

    Off-white to light yellow

    Sequence

    Thr-Ser-Leu-Asp-Ala-Ser-Ile-Ile-Trp-Ala-Met-Met-Gln-Asn

    Sequence Shortening

    TSLDASIIWAMMQN

    运输条件

    Room temperature in continental US; may vary elsewhere.

    储存方式

    Sealed storage, away from moisture and light

    Powder -80°C 2 years
    -20°C 1 year

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

    溶解性数据
    In Vitro: 

    H2O 中的溶解度 : < 0.1 mg/mL (insoluble)

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    In Vivo:

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
    ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.5 mg/mL (Infinity mM); 悬浊液; 超声助溶

      此方案可获得 2.5 mg/mL的均匀悬浊液,悬浊液可用于口服和腹腔注射。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

      生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (Infinity mM); 悬浊液; 超声助溶

      此方案可获得 2.5 mg/mL的均匀悬浊液,悬浊液可用于口服和腹腔注射。

      1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

      20% SBE-β-CD in Saline 的配制(4°C,储存一周):2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。
    动物溶解方案计算器
    请输入动物实验的基本信息:

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    由于实验过程有损耗,建议您多配一只动物的量
    计算结果
    工作液所需浓度 : mg/mL
    纯度 & 产品资料
    参考文献
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称:

     

    * 需求量:

    * 客户姓名:

     

    * Email:

    * 电话:

     

    * 公司或机构名称:

       留言给我们:

    Bulk Inquiry

    Inquiry Information

    产品名称:
    Disitertide TFA
    目录号:
    HY-P0118A
    需求量: